Latest News

The $1.5 billion project builds on more than $3 billion the global biopharmaceutical company has already invested in its United States operations since 2018 and is expected to create at least 300 new jobs alongside hundreds of construction roles.

Telix Pharmaceuticals (ASX:TLX) has reported positive early outcomes from the first part of its global Phase 3 ProstACT study, marking an important step in the development of a new targeted treatment for advanced prostate cancer.

Imugene (ASX:IMU) has reported encouraging early clinical results from its ongoing Phase 1b study of Azer Cel, an off-the-shelf CAR T cell therapy designed to treat several advanced blood cancers.

Island Pharmaceuticals (ASX:ILA) has entered a strategic research collaboration with the Burnet Institute to expand the development potential of its antiviral drug portfolio and target a broader range of global viral threats.

New research presented by Amplia Therapeutics (ASX:ATX) is drawing attention to a potential strategy that could improve the effectiveness of an emerging class of cancer treatments targeting KRAS mutations, one of the most widely studied drivers of solid tumours worldwide.

Nanosonics (ASX:NAN) has reached an important regulatory milestone after the United States Food and Drug Administration granted 510(k) clearance that broadens the range of endoscopes compatible with the company’s CORIS system.

Lateral Pharma has secured a significant intellectual property milestone with the granting of a U.S. composition-of-matter patent for LAT9997, the company’s next-generation therapeutic candidate targeting the LanCL pathway for the treatment of neuropathic pain.

Firebrick Pharma (ASX:FRE) is preparing for a pivotal year in 2026 as it accelerates the commercial expansion of its Nasodine product portfolio and pushes into new international markets.

Australian biotechnology company AdAlta (ASX:1AD) has expanded the clinical advisory board of its subsidiary AdCella as it prepares to advance a promising new CAR-T cell therapy for solid cancers into further development and clinical testing.

Island Pharmaceuticals (ASX:ILA) has strengthened its position in the United States biodefence research network through a new collaborative agreement aimed at accelerating the development of its antiviral drug candidate, Galidesivir, for the treatment of Marburg virus disease.

PYC Therapeutics (ASX:PYC) has completed the retail component of a major capital raising, adding approximately $47 million to its funding as the biotechnology company continues to advance its precision medicine programs for genetic diseases.

Alterity Therapeutics (ASX:ATH) has appointed internationally recognised neurologist Dr Daniel O Claassen as Chief Medical Advisor as the company prepares to advance its lead therapy into a pivotal late-stage clinical trial.